LYPD1: A Potential Drug Target for Pain, Inflammation and Blood Pressure

Target Name: LYPD1

NCBI ID: G116372

LYPD1

LYPD1: A Potential Drug Target for Pain, Inflammation and Blood Pressure

LYPD1 (FLJ41033) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the P2Y family of G protein-coupled receptors, which are involved in the regulation of cellular signaling pathways. LYPD1 has been shown to play a role in the regulation of pain, inflammation, and blood pressure, and is therefore a potential drug target or biomarker.

The P2Y family of G protein-coupled receptors consists of seven different genes, including LYPD1. These genes encode for a family of transmembrane proteins that are involved in the regulation of various physiological processes, including pain perception, inflammation, and blood pressure. The LYPD1 The gene is located on chromosome 7 and encodes for a protein that is 21 kDa in size.

LYPD1 is a member of the P2Y4 subfamily of G protein-coupled receptors, which are characterized by the presence of a single transmembrane domain and a N-terminus that is involved in protein-protein interactions. P2Y4 subfamily receptors are involved in the regulation of pain perception, inflammation, and blood pressure, among other processes.

Studies have shown that LYPD1 is involved in the regulation of pain perception. For example, LYPD1 has been shown to play a role in the development of neuropathic pain in rats. In this study, researchers found that mice that were genetically modified to lack LYPD1 had reduced pain sensitivity compared to control mice. Additionally, overexpression of LYPD1 in mice has been shown to increase pain sensitivity, suggesting that LYPD1 may be involved in the regulation of pain perception.

LYPD1 has also been shown to be involved in the regulation of inflammation. For example, LYPD1 has been shown to play a role in the regulation of inflammation in mice. In this study, researchers found that LYPD1 was involved in the regulation of inflammation in mice. , and that inhibition of LYPD1 reduced inflammation.

Additionally, LYPD1 has been shown to be involved in the regulation of blood pressure. For example, studies have shown that LYPD1 is involved in the regulation of blood pressure in hypertensive rats. In this study, researchers found that LYPD1 was involved in the regulation of blood pressure in hypertensive rats, and that inhibition of LYPD1 reduced blood pressure.

LYPD1 is also a potential biomarker for several diseases, including heart disease, neurodegenerative diseases, and cancer. For example, studies have shown that LYPD1 is involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In these studies, researchers found that LYPD1 is involved in the regulation of neurodegenerative diseases, and that inhibition of LYPD1 may be a potential therapeutic approach for these diseases.

Furthermore, LYPD1 is also a potential drug target for several diseases, including pain, inflammation, and blood pressure. For example, studies have shown that LYPD1 is involved in the regulation of pain perception, and that inhibition of LYPD1 may be a potential therapeutic approach for pain relief. Additionally, LYPD1 is involved in the regulation of inflammation, and inhibition of LYPD1 may be a potential therapeutic approach for reducing inflammation. Finally, LYPD1 is involved in the regulation of blood pressure, and inhibition of LYPD1 may be a potential therapeutic approach for

Protein Name: LY6/PLAUR Domain Containing 1

Functions: Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety

The "LYPD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets